Stockreport
Veopoz (Regeneron Pharmaceuticals) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
Regulatory support and innovation in monoclonal antibody therapies further bolster growth potential in rare disease management. Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Veopoz Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. The Veopoz market is experiencing significant growth driven by improved understanding of complement-mediated diseases and advancements in precision medicine. The historic growth period benefitted from developments in monoclonal antibody engineering, and increased diagnosis of rare immune disorders. Furthermore, the availability of orphan drug development programs and supportive regulatory incentives have encouraged expansion. Looking into the forecast period, the market's expansion is anchored in personalized immunotherapy strategies, increased investments in complement biology research, and adoption of precision medicine specific to rare diseases. The rise in health
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | REGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
REGN alerts
REGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
NEWS
NEWS
- How The Regeneron (REGN) Story Is Shifting As Dupixent And Pipeline Expectations Reset [Yahoo! Finance][Yahoo! Finance]
- Is Regeneron Pharmaceuticals, Inc. (REGN) A Good Stock To Buy? [Yahoo! Finance][Yahoo! Finance]
- In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making [Yahoo! Finance][Yahoo! Finance]
- Regeneron Pharmaceuticals, Inc. (REGN) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha][Seeking Alpha]
- Regeneron: Fairly Valued Now After A Stellar Upswing [Seeking Alpha][Seeking Alpha]
- More
REGN
SEC Filings
SEC Filings
- 3/3/26 - Form 4
- 2/23/26 - Form 4
- 2/19/26 - Form 144
- REGN's page on the SEC website
- More